Sign In
Buy INBX
$95.22
+1.59 (+1.70%)
At Close: Jun 03, 2026
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the previously
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
11:25am, Wednesday, 28'th Feb 2024
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.73 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.95 per share a year ago.
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
09:15am, Wednesday, 28'th Feb 2024
SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeli
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
07:01am, Wednesday, 24'th Jan 2024
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
03:31pm, Tuesday, 23'rd Jan 2024
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
12:03pm, Tuesday, 23'rd Jan 2024
MILWAUKEE , Jan. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Inhibrx (Nasdaq: INBX) in connection with its transaction with Sanofi. Click here to learn how to join https://www.ademilaw.com/cas
Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline
11:45am, Tuesday, 23'rd Jan 2024
Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to tr
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
09:33am, Tuesday, 23'rd Jan 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms o
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
01:00am, Tuesday, 23'rd Jan 2024
Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 ass
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
09:15am, Thursday, 02'nd Nov 2023
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today ann
Inhibrx Announces Participation in Upcoming Scientific Conferences
04:00pm, Wednesday, 18'th Oct 2023
SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today an
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
04:00pm, Tuesday, 19'th Sep 2023
SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announc
Andreas Halvorsen's Firm Ups Inhibrx Stake
04:26pm, Friday, 01'st Sep 2023
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% fol
Inhibrx Announces $200 Million Private Placement Financing
09:00am, Tuesday, 29'th Aug 2023
SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncolog
